Fox Chase Cancer Center Partners Sites among Select Group Taking Part in National Research Project
Philadelphia (August 1, 2012)—Three hospitals from Fox Chase Cancer Center Partners—Fox Chase’s affiliate network of community hospitals—have qualified to take part in the National Comprehensive Cancer Network® (NCCN®) Affiliate Research Project (ARP). Developed by the NCCN Oncology Research Program (ORP), the project is dedicated to improving patient outcomes and advancing clinical research through collaboration among NCCN; the 21 NCCN member institutions, including Fox Chase Cancer Center; and their community-based affiliate networks.
Affiliate sites of the ORP will have access to new and innovative cancer drugs for their patients in collaboration with NCCN member institutions, and principal investigators of NCCN-funded studies will have access to NCCN-qualified community sites.
Fox Chase Cancer Center Partners sites that will take part in the project are:
- Virtua, including Hematology Oncology Associates of South Jersey, Mt. Holly, N.J.; and Comprehensive Cancer and Hematology Specialists, Voorhees, N.J.
- AtlantiCare Cancer Care Institute, Egg Harbor Township, N.J.
- South Jersey Healthcare, including Southern Oncology-Hematology Associates, PA, Vineland, N.J.; South Jersey Radiation Oncology, P.C., Vineland, N.J.; and The Minniti Center - Medical Oncology & Hematology, Mickleton, N.J.
“For 25 years, Fox Chase Cancer Center Partners has provided outstanding cancer care as well as a strong foundation for cancer research and education through its community hospital sites. Participation in the NCCN Affiliate Research Project demonstrates the program’s ongoing commitment to further clinical research and offer exciting new opportunities to the communities we serve,” said Mark L. Sobczak, MD, chief network officer and senior vice president for networks of Fox Chase Cancer Center Partners. “We are especially pleased to congratulate Virtua Fox Chase Cancer Program, AtlantiCare Cancer Care Institute, and South Jersey Healthcare Cancer Program on the outstanding achievement of qualifying for this national project.”
The NCCN ORP is organized to obtain funding for scientifically meritorious research projects at NCCN member institutions. The NCCN Investigator Steering Committee—a group of senior research physicians appointed by each NCCN member institution—sets the program’s policies and standards. To date, the program has received more than $36 million in research grants from pharmaceutical and biotech companies to support investigator-initiated trials including, but not limited to, evaluation of innovative regimens, mechanism of action, and exploration of extended uses for specific agents.
In addition to Fox Chase Cancer Center Partners, four other community sites—three affiliates of the Seattle Cancer Care Alliance and one affiliate of the University of Alabama at Birmingham Cancer Care Network—will participate in the ARP. NCCN plans to approve a minimum of three additional sites this year to potentially support more than 50 actively enrolling clinical trials.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).